We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

75 hedge funds and large institutions have $55.1M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 30 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more capital invested

Capital invested by funds: $35.5M → $55.1M (+$19.7M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10% less funds holding

Funds holding: 83 → 75 (-8)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

50% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 30

Holders
75
Holders Change
-8
Holders Change %
-9.64%
% of All Funds
1.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
15
Reduced
30
Closed
23
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
TC
Trium Capital
United Kingdom
+$1.45M
2
ACM
ADAR1 Capital Management
Texas
+$1.21M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$535K
4
Citadel Advisors
Citadel Advisors
Florida
+$401K
5
N
Natixis
France
+$269K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$2.05M
2
Millennium Management
Millennium Management
New York
-$1.77M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.15M
4
N
Nuveen
North Carolina
-$787K
5
Two Sigma Investments
Two Sigma Investments
New York
-$686K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
76
Federated Hermes
Pennsylvania
– -$297K -345,381 Closed
D.E. Shaw & Co
77
D.E. Shaw & Co
New York
– -$265K -308,104 Closed
Deutsche Bank
78
Deutsche Bank
Germany
– -$183K -212,944 Closed
Squarepoint
79
Squarepoint
New York
– -$183K -212,916 Closed
BCM
80
Bridgeway Capital Management
Texas
– -$168K -195,000 Closed
Man Group
81
Man Group
United Kingdom
– -$103K -119,740 Closed
Ameriprise
82
Ameriprise
Minnesota
– -$100K -116,751 Closed
State of Wisconsin Investment Board
83
State of Wisconsin Investment Board
Wisconsin
– -$59.3K -69,000 Closed
Mackenzie Financial
84
Mackenzie Financial
Ontario, Canada
– -$54.1K -62,964 Closed
Ohio Public Employees Retirement System (OPERS)
85
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$41.6K -48,424 Closed
Russell Investments Group
86
Russell Investments Group
United Kingdom
– -$37.5K -43,598 Closed
Susquehanna International Group
87
Susquehanna International Group
Pennsylvania
– -$30.1K -35,092 Closed
PFCS
88
Pale Fire Capital SE
Czech Republic
– -$26.4K -30,700 Closed
Prudential Financial
89
Prudential Financial
New Jersey
– -$25.6K -29,785 Closed
RJA
90
Raymond James & Associates
Florida
– -$17.8K -20,714 Closed
HF
91
HRT Financial
New York
– -$11K -12,821 Closed
US Bancorp
92
US Bancorp
Minnesota
– -$11K -12,751 Closed
Walleye Capital
93
Walleye Capital
New York
– -$10.6K -12,380 Closed
QT
94
Quantbot Technologies
New York
– -$4.55K -5,300 Closed
Carson Wealth (CWM LLC)
95
Carson Wealth (CWM LLC)
Nebraska
– -$948 -639 -99%
Qube Research & Technologies (QRT)
96
Qube Research & Technologies (QRT)
United Kingdom
– -$330 -384 Closed
Simplex Trading
97
Simplex Trading
Illinois
– -$177 -119 -81%
C
98
Covestor
United Kingdom
– -$4 -3 -5%
1 2 3
4

NGM Hedge Fund Activity: Q1 2024 in Review

75 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2024, worth a combined $55.1M — up 56% from $35.5M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of NGM and 15 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 15 added.

The largest buyer was Trium Capital, opening a new position worth an estimated $1.45M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.05M sold.

  • 75 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2024, down from 83 in Q4 2023.
  • Funds reported $55.1M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2024, up 56% quarter-over-quarter.
  • 15 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2024 and 23 closed out, a net change of -8 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2024 was Trium Capital, an estimated $1.45M added.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2024 was EcoR1 Capital, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2024.